Evidence map›Paper›PMID 27759023›Full record

ArticleMucosal immunology2017

MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates.

J M Greene, P Dash, S Roy, C McMurtrey, W Awad, J S Reed, K B Hammond, S Abdulhaqq, H L Wu, B J Burwitz and 24 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mucosal immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 103 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Transcriptomic profile ofFrontiers in immunology · 2023
    Article
  17. Role of MHC class I pathways inFrontiers in cellular and infection microbiology · 2023
    Review
  18. Review
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 6 institutions in 2 countries.

J M GreeneVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
P DashDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
S RoyDepartment of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois, USA.
C McMurtreyDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
W AwadDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
J S ReedVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
K B HammondVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
S AbdulhaqqVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
H L WuVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
B J BurwitzVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
B F RothVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
D W MorrowVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
J C FordVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
G XuVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
J Y BaeVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
H CrankVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
A W LegasseVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
T H DangUNSW Australia, Sydney, New South Wales, Australia.
H Y GreenawayUNSW Australia, Sydney, New South Wales, Australia.
M KurniawanUNSW Australia, Sydney, New South Wales, Australia.
M C GoldPulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA.
M J HarriffPulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA.
D A LewinsohnMolecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA.
B S ParkVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
M K AxthelmVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
J J StantonVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
S G HansenVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
L J PickerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
V VenturiKirby Institute for Infection and Immunity, UNSW Australia, Sydney, New South Wales, Australia.
W HildebrandDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
P G ThomasDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
D M LewinsohnPulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA.
E J AdamsDepartment of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois, USA.
J B SachaVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Oregon Health & Science University · USOregon National Primate Research Center · USSt. Jude Children's Research Hospital · USUNSW Sydney · AUUniversity of Chicago · USUniversity of Oklahoma Health Sciences Center · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Recognition of Mtb-infected Cells by CD8+ T LymphocytesR01AI048090 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M. · 2001 to 2016
$4.2M
A universal MHC-E-restricted T cell vaccine for HIVR01AI117802 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SACHA, JONAH B. · 2015 to 2018
$3.5M
Mechanisms to diversify repertoire and modify T cell activity after infectionR01AI107625 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI THOMAS, PAUL G. · 2013 to 2017
$2.3M
Impact of retroviral infection on non-classical, mycobacteria-specific T cells.R21AI127125 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HANSEN, SCOTT G, SACHA, JONAH B. · 2016 to 2017
$493k
Mtb uptake and antigen presentation in human lung epithelial cellsIK2CX000538 · VA · PORTLAND VA MEDICAL CENTER · PI HARRIFF, MELANIE J · 2012 to 2016
–
Recognition of Mtb-Infected Cells by Non-Classically Restritcted CD8+ T CellsI01BX000533 · VA · PORTLAND VA MEDICAL CENTER · PI LEWINSOHN, DAVID M. · 2011 to 2024
–
BLRD VA I01 BX000533CSRD VA IK2 CX000538NIAID NIH HHS R01 AI048090NIAID NIH HHS R01 AI107625NIAID NIH HHS R01 AI117802NIAID NIH HHS R21 AI127125NIH HHS P51 OD011092
6 · The paper itself

Abstract

Studies on mucosal-associated invariant T cells (MAITs) in nonhuman primates (NHP), a physiologically relevant model of human immunity, are handicapped due to a lack of macaque MAIT-specific reagents. Here we show that while MR1 ligand-contact residues are conserved between human and multiple NHP species, three T-cell receptor contact-residue mutations in NHP MR1 diminish binding of human MR1 tetramers to macaque MAITs. Construction of naturally loaded macaque MR1 tetramers facilitated identification and characterization of macaque MR1-binding ligands and MAITs, both of which mirrored their human counterparts. Using the macaque MR1 tetramer we show that NHP MAITs activated in vivo in response to both Bacillus Calmette-Guerin vaccination and Mycobacterium tuberculosis infection. These results demonstrate that NHP and human MR1 and MAITs function analogously, and establish a preclinical animal model to test MAIT-targeted vaccines and therapeutics for human infectious and autoimmune disease.

Indexed as

AnimalsCells, CulturedDisease Models, AnimalHistocompatibility Antigens Class IHumansMacaca mulattaMinor Histocompatibility AntigensMucosal-Associated Invariant T CellsMycobacterium tuberculosisProtein BindingProtein EngineeringReceptors, Antigen, T-CellSequence AlignmentSpecies SpecificityT-LymphocytesTuberculosisHistocompatibility Antigens Class IMinor Histocompatibility AntigensMR1 protein, humanReceptors, Antigen, T-CellTuberculosis Vaccines

Identifiers

PMID27759023
PMCPMC5397382
OpenAlexW2537678836

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.